SURVEY HEMODINAMIC, ELECTROLYTES, ACID-BASE CHANGES AND COAGULATION DISORDERS IN DDS TREATED WITH HydroxyEthyl Starch 130 6% SOLUTION

Minh Tien Nguyen, Huu Nhan Nguyen, Vu Phuong Thy Le, Thi Gia Hanh Nguyen, Thanh Hong Phan, Thi Hoang Thu Nguyen

Main Article Content

Abstract

Objectives: To explore hemodynamic, electrolytes, acid-base changes and coagulation disorders in Dengue shock syndrome (DDS) treated with HydroxyEthyl Starch 130 6% solution  admitted at City children’s hospital from June 2020 till June 2021.


Method: Retrospective case series study


Results: 60 DDS children treated with HydroxyEthyl Starch 130 6% solution were investigated. The mean age was 5.4 years old, ranging from 14 months old to 14 years old. Assessment of hemodynamic changes within 24 hours after HES 130 6% infusion showed that shock condition improved with reduced mean heart rate at 4th hours (121.3 vs.101.6),  widened pulse pressure at first hour while systolic, diastolic, mean blood pressures stabilized at level of  92.5 – 108.4 mmHg, 73.2-66.2 mmHg, 78.6-82.7 mmHg. Mean hematocrit at one hour after HES 130 6% infusion was 38.6%, significantly improved from 43.4% at baseline and stabilized at 37.5-38.4% thereafter. There were no significant abnormal changes in electrolytes, acid-base, or coagulation. The average amount of HES 130 6% solution used was 133.8 ± 15.3 ml/kg over a mean duration of 25.3 ± 2.6 hours. Complications caused possibly by infusion of HES 130 6% solution including respiratory failure (56.7%) due to pleural and peritoneal effusion; gastrointestinal bleeding (8.3%). No infusion tremor or anaphylaxis was observed during infusion of HES 130 6% solution. The failure rate with HES 130 6% solution, switching to HES 200 6% or dextran 40 10% was 38.3%. No death was documented.


Conclusions: The study helps clinicians have an additional option of HES 130 6% solution in the treatment of dengue shock syndrome when the source of high-molecular solution is scarce such as HES 200 6%, dextran 40 10%. However, the application of HES 130 6% solution is only for DSS, not for severe DSS and acute respiratory failure occurring during infusion needs to be noted and supported timely.

Article Details